August 1, 2016
A very happy August to you. I hope your summer has been pleasant thus far and that you are finding some “cooler” moments to spend outdoors. This will be my last message to you as President of NYACC, as my role now shifts to serving as President of the New York Cardiological Society.
We have scheduled several upcoming events for you, and I am excited about all of them. Our 88th Annual Scientific Session and 26th Annual Meeting will be held October 7-8 at the Hotel Eventi in NYC. We have a wonderful lineup of speakers, including Drs. Joseph Alpert, Sabahat Bokhari, Sarwat Chaudhry, Kumar Dharmarajan, John Dodson, Mathew Maurer, Nicole Orr, and Mike Rich, who are experts on aging in the field of CV care. This should be a great event, and I hope to see many of you there.
We have been working hard to provide greater member benefit to you, and as such, there will be no fee (for NYACC members) for this year’s Scientific Session. In addition, the night prior (Oct. 7th), we have added a free member reception of cocktails and hors d’oeuvres. This event will also be held at the Hotel Eventi to give you all the opportunity to socialize and to network. If you plan on attending, you must register for both events, as space is limited.
You can register now at https://ny-acc.org/2016annualmtg or by calling (212) 686-0228.
If you are a Fellow In Training (FIT) or a fellowship director, consider being a part of the Young Investigators’/Case Presenters’ Award Competition. It is a wonderful opportunity to present your research to a distinguished group of cardiovascular professionals at one of our biggest events of the year.
I am also happy to share that we will be co-sponsoring this year’s “Janet Baldwin Dinner/Lecture,” a 50-year-running lecture that features a prominent pediatric cardiologist, with the Pediatric Cardiology Society of Greater New York. More details are forthcoming.
As a final note, with implementation and congressional oversight of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) well underway, it is a critical time for us to be in Washington D.C. to personally deliver cardiology’s message. Several of your NYACC leaders will be representing our Chapter next month in D.C. during ACC’s 2016 Legislative Conference. If you wish to join us, you can register online here.
Have a great rest of your summer; I’ll see you in October!
Tim Malins, MD, FACC | Upstate Governor
President, New York State Chapter,
American College of Cardiology
Heart Failure Management
Last month the ACC held its Emerging Strategies for Heart Failure Roundtable, which brought together a wide group of experts and relevant stakeholders to examine the practical barriers and gaps in care and/or knowledge around HF management.
Discussions focused on three primary areas: 1) Accountability in Heart Failure: The Challenges and Complementary Nature of Adherence, Measurement and Evolving Science; 2) New Medications, New Choices – Which Guideline Directed Medical Therapy Should be Used for Optimal Medical Therapy; and 3) Prevention of AHA Stage C Heart Failure.
The Roundtable is the first step in launching the College’s new “Succeed in Managing Heart Failure” Initiative, a multidisciplinary quality program designed to improve care for heart failure patients. Outcomes from the Roundtable will be used to inform the development of clinical tools and patient resources.
ACC Among Best Places to Work
The American College of Cardiology was selected as one of Modern Healthcare’s Best Places to Work in Healthcare for 2016.
Increasing staff and member knowledge and skills is one of the College’s top priorities. This honor is truly a reflection on the College’s efforts to ensure that staff are able to best support our mission to transform cardiovascular care and improve heart health.
Specific rankings will be announced on Oct. 6 at the Modern Healthcare awards gala in New Orleans.
News from ACC
Recommendations on two new heart failure (HF) medications are detailed in a focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure, released May 20 by the ACC, American Heart Association (AHA) and Heart Failure Society of America and published in theJournal of the American College of Cardiology.
The focused update includes the addition of an angiotensin receptor-neprilysin inhibitor (ARNI) (valsartan/sacubitril), and a sinoatrial node modulator (ivabradine) to the list of treatment options for Stage C HF patients with a reduced ejection fraction.
“This document details the benefits and risks of these new therapies so that patients at high risk can be directed towards alternative therapies,” explains Clyde W. Yancy, MD, MSc, MACC, chair of the writing committee. Read more on ACC.org.